Empower Pharmacy

02/27/2026

Another meaningful outcome for personalized medicine.

Across the country, state-level policies continue to shape the future of personalized medicine. This legislative session, proposed bills in Arizona (HB 4036), Mississippi (SB 2544), and Washington (HB 2613) sought changes that could have limited access to compounded medications and constrained providers’ ability to tailor treatment to individual patient needs. The good news: none of these bills advanced.

The implications were significant. Passage would have reduced therapeutic options, narrowed pathways to care, and restricted individualized treatment, particularly when commercially available products are insufficient.

We believe responsible policymaking should protect patient safety while preserving access to appropriate, necessary treatment options. For many patients, compounded medications are not optional. They are essential. That belief drives our engagement in policy discussions that directly affect access to personalized medicine.

Throughout the session, Empower’s Government Affairs team remained actively engaged, working with policymakers, collaborating with stakeholders, and ensuring the perspectives of patients and providers, along with the real-world impact of these decisions, were represented in the broader conversation.

Protecting patient choice and provider decision-making requires sustained, thoughtful advocacy. We remain committed to supporting policies that safeguard access to personalized medicine wherever it may be at risk.

02/25/2026

Meet patients where they are.

Empower provides GLP-1 weight management support products in forms that fit different preferences, including injectables and orals, available in multiple strengths to support customized plans.

In stock and ready to ship:
• Semaglutide / Cyanocobalamin Injection
• Semaglutide / Methylcobalamin ODT
• Tirzepatide / Niacinamide Injection
• Tirzepatide ODT

Get Started Today: https://bit.ly/4tLLGNE

02/20/2026

📍 Dallas, we're coming for you!
Join us at The HEAL Conference | March 5–7 and stop by Booth S8 to explore how Empower can help you:

✅ Expand treatment options
✅ Support individualized patient care
✅ Stay ahead in functional medicine

From education to innovation, HEAL brings the clinicians and tools shaping what’s next in patient care. Let’s connect in person and talk what’s possible for your practice.

02/19/2026

A bill moving through the Colorado Legislature could restrict compounding and limit access to customized medications for patients across the state.

For providers and pharmacists, this means fewer options to meet individual patient needs. For patients, it means potential disruptions to therapies they rely on.

If you live or practice in Colorado, join our Government Affairs team in contacting your State Legislators and urge them to oppose this legislation.

Lawmakers need to hear directly from the communities who understand the impact.

Take action here: https://bit.ly/4qO9s9c

02/18/2026

We’re excited to welcome Goldi Goel to as our new Chief Technology Officer.

Goldi joins us at a pivotal moment as we continue investing in the systems and platforms that power personalized medicine at scale. He will lead our technology transformation, building an AI-forward platform grounded in strong governance, security, and reliability.

Goldi’s focus on turning innovation into real, measurable impact, combined with his more than two decades of experience building and scaling technology in highly regulated environments, including at Albertsons, Amazon, and Nvidia, makes him a natural and valuable addition to the team.

Just as important, Goldi believes technology should simplify complexity and strengthen trust across the organization.

We’re excited for the next phase of our technology journey under Goldi’s leadership.

Welcome to the team, Goldi!

02/17/2026

Before a medication ever reaches a patient, a pharmacist has reviewed the therapy, ensured a comprehensive understanding of prescriber intent, and stood confidently behind how it supports the best outcomes for that patient.

For many patients, that pharmacist is the final clinical checkpoint before treatment begins. They are far more than processing agents. They are essential partners in therapeutic care.

That level of responsibility was on full display at the FIP World Congress of Pharmacy in Copenhagen, where more than 3,000 pharmacists from 127 countries gathered to discuss how the profession is evolving and where it must lead next.

In a recent episode of Pharmacy Times’ Pharmacy Focus Podcast, Empower’s Director of Government Affairs, Derek Webb, makes the case for how lessons from FIP can strengthen pharmacy practice in the U.S., from over-the-counter allergy care to scope and policy modernization.

We’re proud to have leaders representing in the conversations shaping the future of pharmacy. If you care about where the profession is headed and the role pharmacists play within the care team, this discussion is worth your time.

https://bit.ly/4qDjmKN

Derek Webb and Dennis Williams discuss key global learnings from the FIP World Congress of Pharmacy, highlighting how pharmacists worldwide are leading proactive OTC allergy care and what practical strategies US community pharmacies can adopt.

02/13/2026

A meaningful step forward for personalized medicine in women’s health.

The FDA has approved updated labeling for menopausal hormone therapy products, reflecting a more current understanding of the evidence and how these therapies are used in practice.

When regulation evolves alongside science, patients benefit. Women deserve accurate information, thoughtful risk evaluation, and access to personalized treatment decisions made in partnership with their clinicians.

We’re encouraged to see this progress.

Read more: https://bit.ly/4rTUCPq

02/12/2026

Available now – when flexibility matters.

Testosterone Cypionate Injection remains a commonly prescribed therapy in hormone management. Empower has long offered multiple strengths and dosage options, giving providers the ability to tailor therapy based on patient-specific considerations and clinical judgment.

Individualized compounding. Trusted formulations. Built to support your practice.

Explore Testosterone Cypionate options: https://bit.ly/3ZsEtUW



Compounded drug products are available only through a valid prescription from your healthcare provider. Compounded products are not FDA-approved and have not been evaluated by the FDA for safety or efficacy.

02/11/2026

We’re thrilled to welcome Marcos Roberto da Costa to Empower as our new Chief Operating Officer.

Marcos brings decades of global leadership experience across pharmaceutical manufacturing, operations, and quality, with a proven track record of leading complex, highly regulated organizations at scale. Throughout his career, he has built exceptional leadership teams and translated strategy into disciplined ex*****on across the U.S., Latin America, Europe, and Asia.

At Empower, Marcos will focus on strengthening our operational foundation to support scalable, patient-first growth. His leadership, including 27 years at Merck, is grounded in operational excellence, continuous improvement, and an unwavering commitment to quality, compliance, and reliability.

Just as important, Marcos is deeply passionate about developing people, simplifying complexity, and building systems that empower teams to deliver sustainable results for patients, customers, and the organization.

Welcome to the team, Marcos!

02/04/2026

Compounding plays a vital role in healthcare. For many patients and providers, it serves as the bridge between standardized medicine and truly personalized care.

It’s for this reason that Empower views advocacy as a core responsibility and central to our work, supporting providers’ ability to exercise clinical judgment and protecting patient access to individualized therapies.

We’re encouraged by recent action in Virginia, where HB 917, a bill that could have limited access to compounded medications, did not advance this legislative session. Its delay allows additional time for thoughtful evaluation, open dialogue, and meaningful input from providers, patients, and other stakeholders.

This work matters because access matters.

01/29/2026

The FDA is taking a fresh look at how testosterone replacement therapy (TRT) is labeled and regulated. They have opened a public comment period to gather real-world experiences with TRT.

Patients and clinicians are invited to share their stories and submit comments directly to the FDA. Public comment is one of the best direct ways to help inform regulatory decisions.

For those who want to contribute, the comment window closes on February 9th. https://bit.ly/4k7R5ua

01/23/2026

We’re monitoring the winter storm expected to impact parts of the country this weekend. At this time, our operations are running as usual, and we’ll continue to assess conditions to support our teams’ safety. We’ll share updates if anything changes, including any shipping impacts. Please check our website and customer portals for the latest information. Stay safe.